| MeSH term | MeSH ID | Detail |
|---|---|---|
| Glioma | D005910 | 112 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Seizures | D012640 | 87 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Mueller AR et al. | Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. | 1994 | Transplant. Proc. | pmid:7527951 |
| Tai J et al. | In vivo function of pig islet xenografts in immunosuppressed diabetic mice. | 1995 | Transplant. Proc. | pmid:8539968 |
| Schreier MH et al. | Inhibition of T-cell signaling pathways by immunophilin drug complexes: are side effects inherent to immunosuppressive properties? | 1993 | Transplant. Proc. | pmid:7679818 |
| Tze WJ et al. | Immunohistochemical studies of pig islet xenograft in rats immunosuppressed with FK 506. | 1994 | Transplant. Proc. | pmid:7513470 |
| Tolba RH et al. | Conversion to Neoral for tacrolimus-related adverse effects in liver transplant recipients and improvement in quality of life. | 2001 Nov-Dec | Transplant. Proc. | pmid:11750475 |
| Zheng B et al. | Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo. | 1991 | Transplant. Proc. | pmid:1703717 |
| Rostaing L et al. | Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636520 |
| Hu RH et al. | Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients. | 2000 | Transplant. Proc. | pmid:11119894 |
| Yashima J et al. | Successful conversion from tacrolimus to cyclosporine after kidney transplantation. | 2000 | Transplant. Proc. | pmid:11119895 |
| Marin-Gomez LM et al. | Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715867 |
| Montejo M et al. | Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715869 |
| Aktürk S et al. | Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. | 2015 | Transplant. Proc. | pmid:26093738 |
| Shoji T et al. | Long-term acceptance of porcine pulmonary allografts without chronic rejection. | 2005 Jan-Feb | Transplant. Proc. | pmid:15808551 |
| Yamamoto S et al. | FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. | 2005 Jan-Feb | Transplant. Proc. | pmid:15808570 |
| Ortiz de Urbina J et al. | Advagraf de novo in liver transplantation: a single-center experience. | 2011 | Transplant. Proc. | pmid:21486583 |
| Pérez MJ et al. | Cardiovascular risk factors after liver transplantation: analysis of related factors. | 2011 | Transplant. Proc. | pmid:21486587 |
| Ericzon BG et al. | Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. | 1990 | Transplant. Proc. | pmid:1689905 |
| Reyes J et al. | Nutritional management of intestinal transplant recipients. | 1993 | Transplant. Proc. | pmid:7680149 |
| Farghali H et al. | Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. | 1991 | Transplant. Proc. | pmid:1721283 |
| Pirenne J et al. | Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. | 1996 | Transplant. Proc. | pmid:8623447 |
| Liu WT et al. | In vitro generation of tacrolimus metabolites and their detection in whole blood. | 1998 | Transplant. Proc. | pmid:9636590 |
| Jiang H and Kobayashi M | Differences between cyclosporin A and tacrolimus in organ transplantation. | 1999 | Transplant. Proc. | pmid:10455942 |
| Sekido H et al. | Successful conversion from cyclosporine to tacrolimus for immunosuppression. | 2000 | Transplant. Proc. | pmid:11120096 |
| Ali MN et al. | Case series: hemolytic uremic syndrome--another cause of transplant dysfunction. | 2013 | Transplant. Proc. | pmid:24182801 |
| Friemann S et al. | Conversion to tacrolimus in hyperlipidemic patients. | 1999 | Transplant. Proc. | pmid:10576042 |
| Batista F et al. | Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation. | 2012 | Transplant. Proc. | pmid:23146461 |
| Hu RH et al. | Effects of and predictors for tacrolimus rescue therapy among renal transplant patients under cyclosporine-based immunosuppression. | 2004 | Transplant. Proc. | pmid:15518757 |
| Ichimaru N et al. | Risk factors and incidence for lipid abnormalities in kidney transplant patients. | 2015 | Transplant. Proc. | pmid:25891708 |
| Nardo B et al. | Pretransplant xenogeneic blood transfusion combined with FK 506 prolongs hamster-to-rat liver xenograft survival. | 1994 | Transplant. Proc. | pmid:7518112 |
| Abouljoud MS et al. | Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533360 |
| Pan F et al. | FK 506 prolongs survival of liver but not heart mouse-to-rat vascularized xenografts. | 1994 | Transplant. Proc. | pmid:7518113 |
| Wiesner RH et al. | Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. | 1993 | Transplant. Proc. | pmid:7682352 |
| Morozumi K et al. | Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. | 1996 | Transplant. Proc. | pmid:8644331 |
| Bäckman L et al. | Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. | 1995 | Transplant. Proc. | pmid:7533361 |
| McCarthy SA et al. | Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. | 1991 | Transplant. Proc. | pmid:1721314 |
| Söderdahl G et al. | FK 506 improves recovery of bile secretion following orthotopic liver transplantation in man. | 1995 | Transplant. Proc. | pmid:7533362 |
| Zeevi A et al. | Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721315 |
| Tullius SG et al. | ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. | 2003 | Transplant. Proc. | pmid:14529854 |
| Manu MA et al. | Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. | 1999 | Transplant. Proc. | pmid:10578313 |
| Jacob DA et al. | Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. | 2005 | Transplant. Proc. | pmid:15919432 |
| Wasilewski G et al. | Inadequate blood pressure control in orthotopic heart transplant: is there a role of kidney function and immunosuppressive regimen? | 2014 | Transplant. Proc. | pmid:25380929 |
| Ciancio G et al. | Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. | Transplant. Proc. | pmid:27569936 | |
| Wilusz M et al. | Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. | 2014 | Transplant. Proc. | pmid:25380928 |
| Chuang JP et al. | Does immunosuppressive pharmacotherapy affect isoagglutinin titers? | 2008 | Transplant. Proc. | pmid:18929836 |
| Chung YW et al. | Transcriptional activation of nuclear-related factor 2 by FK506 in Jurkat T cells. | 2015 | Transplant. Proc. | pmid:25891728 |
| Tannuri AC et al. | Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy. | 2008 | Transplant. Proc. | pmid:18589165 |
| Serrano J et al. | Tacrolimus is effective in both dual and triple regimens after liver transplantation. | 2002 | Transplant. Proc. | pmid:12176469 |
| Bismuth H | Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. | 1995 | Transplant. Proc. | pmid:7533415 |
| du Toit DF et al. | Tacrolimus (FK506) monotherapy provides potent and significant suppression of allogeneic foetal rat pancreatic allograft rejection. | 1998 | Transplant. Proc. | pmid:9865300 |
| Jain AB et al. | Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant. | 1991 | Transplant. Proc. | pmid:1721347 |
| Wlodarczyk Z et al. | Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. | 2005 | Transplant. Proc. | pmid:15919489 |
| Pohanka E et al. | Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients. | 2005 | Transplant. Proc. | pmid:15919490 |
| Hansen LJ et al. | Early pharmacokinetic profiles of enteral tacrolimus after multivisceral transplantation. | 1997 | Transplant. Proc. | pmid:9142303 |
| Barrera-Pulido L et al. | Clinical relevance and prevalence of polymorphisms in CYP3A5 and MDR1 genes that encode tacrolimus biotransformation enzymes in liver transplant recipients. | 2008 | Transplant. Proc. | pmid:19010156 |
| Tanabe K et al. | Outcome of kidney transplantation from non-heart-beating donors followed by tacrolimus immunosuppression in japan. | 2002 | Transplant. Proc. | pmid:12176493 |
| Gruttadauria S et al. | Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. | 2005 Jul-Aug | Transplant. Proc. | pmid:16182762 |
| Iaria G et al. | Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients. | 2005 Jul-Aug | Transplant. Proc. | pmid:16182769 |
| Wilusz M et al. | Effects of Immunosuppressive Drugs on Serum Fatty Acids of Phospholipids Fraction in Renal Transplant Recipients. | 2016 | Transplant. Proc. | pmid:27496457 |
| Takahara S et al. | Monitoring of FK 506 blood levels in kidney transplant recipients. | 1994 | Transplant. Proc. | pmid:7520623 |
| Watanabe K et al. | Prolongation effect of FK506 on the survival of 3-day preserved kidney allografts in dogs. | 1998 | Transplant. Proc. | pmid:9838579 |
| Wagner K et al. | Effect of FK 506 on excretion of urinary enzymes in rats. | 1991 | Transplant. Proc. | pmid:1721379 |
| Molmenti E et al. | Noncompliance after pediatric liver transplantation. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083164 |
| Wada Y et al. | Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. | 2000 | Transplant. Proc. | pmid:10936371 |
| Li W et al. | High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123209 |
| Sharma A et al. | Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. | 2008 | Transplant. Proc. | pmid:18790252 |
| Schumacher G et al. | Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. | 1996 | Transplant. Proc. | pmid:8962200 |
| Beaunoyer M et al. | Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. | 2002 | Transplant. Proc. | pmid:12176540 |
| Gu B et al. | Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. | 2018 | Transplant. Proc. | pmid:29880353 |
| Lee H et al. | Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience. | 2018 | Transplant. Proc. | pmid:29880348 |
| Nakao A et al. | Changes of allo-intestinal graft survival and intragraft cytokine expression by bone marrow augmentation with tacrolimus treatment in rats. | 2001 Feb-Mar | Transplant. Proc. | pmid:11266851 |
| Alessiani M et al. | Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. | 2000 | Transplant. Proc. | pmid:10995933 |
| Ricordi C et al. | Human islet allotransplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721410 |
| Stütz A | Immunosuppressive macrolides. | 1992 | Transplant. Proc. | pmid:1379762 |
| Harihara Y et al. | Effects of interferon alpha/beta on cardiac allografts. | 1996 | Transplant. Proc. | pmid:8658645 |
| Hoshino Y et al. | FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083547 |
| Kato Y et al. | Epidermal growth factor enhances the intestinal adaptation of small bowel allografts in the postoperative period. | 2000 | Transplant. Proc. | pmid:10995935 |
| Tze WJ et al. | Long-term survival of islet allografts in diabetic rats treated with FK 506. | 1991 | Transplant. Proc. | pmid:1721411 |
| Chiba K et al. | FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. | 1999 Feb-Mar | Transplant. Proc. | pmid:10083549 |
| Kahan BD | High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. | 1998 | Transplant. Proc. | pmid:9723224 |
| Keown PA and Primmett DR | Cyclosporine: the principal immunosuppressant for renal transplantation. | 1998 | Transplant. Proc. | pmid:9723252 |
| Armenti VT et al. | Pregnancy outcomes in female renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9723259 |
| Mendes J et al. | Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. | 2009 | Transplant. Proc. | pmid:19376366 |
| Khwaja K et al. | Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression. | 2002 | Transplant. Proc. | pmid:12176621 |
| Beckebaum S et al. | Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. | 2004 | Transplant. Proc. | pmid:15621120 |
| Rigotti P et al. | Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. | 2002 | Transplant. Proc. | pmid:12176623 |
| Rintala JM et al. | The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. | 2006 | Transplant. Proc. | pmid:17175234 |
| Ishikawa S et al. | Management of Juvenile Idiopathic Arthritis in ABO-incompatible Kidney Transplantation: A Case Report. | 2018 | Transplant. Proc. | pmid:29661455 |
| Del Castillo D | Analysis of primary and recurrent rejection following renal transplantation in a large, comparative, multicentre trial. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267283 |
| Yokomise H et al. | Immunosuppressive effects of FK 506 in canine lung transplantation. | 1991 | Transplant. Proc. | pmid:1721442 |
| McCauley J et al. | Renal transplantation under FK 506 in African-Americans: early experience. | 1993 | Transplant. Proc. | pmid:7689270 |
| Pirsch JD | Mycophenolate mofetil, tacrolimus, Neoral: from clinical trials to the clinic. | 1998 | Transplant. Proc. | pmid:9723448 |
| Antoine C et al. | Vascular microthrombosis in renal transplant recipients treated with tacrolimus. | 1998 | Transplant. Proc. | pmid:9745577 |
| Velioglu A et al. | Association of BK Virus Titers With Lymphocyte Count in Renal Transplant Patients. | 2015 | Transplant. Proc. | pmid:26093733 |
| Kiji T et al. | Relationship between immunological rejection and matrix GLA protein in cryopreserved vascular allografts. | 2004 | Transplant. Proc. | pmid:15561265 |
| Owen ER et al. | Peripheral nerve regeneration in human hand transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267484 |
| Molmenti EP et al. | Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267487 |
| Barak S et al. | Alveolar bone height in patients after liver transplantation. | 2000 | Transplant. Proc. | pmid:10856558 |
| Marcus N et al. | Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. | 1998 | Transplant. Proc. | pmid:9636460 |
| Nanmoku K et al. | Effective and Safe Reduction of Conventional Immunosuppressants Using Everolimus in Maintenance Kidney Transplant Recipients. | 2017 | Transplant. Proc. | pmid:28923615 |
| Girman P et al. | Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. | 2010 Jul-Aug | Transplant. Proc. | pmid:20692391 |